Home Page
About Us
Areas Of
Research
Patients &
Families
Health Care
Professionals
Sponsors
Monthly Archives
2011-12
(6)
2011-09
(1)
2011-08
(5)
2011-02
(1)
2010-12
(3)
2010-08
(1)
2010-07
(3)
2010-06
(1)
2010-03
(3)
2010-01
(1)
2009-12
(4)
2009-10
(2)
2009-09
(2)
2009-08
(2)
2009-06
(1)
2009-05
(1)
2009-04
(2)
2009-03
(7)
2009-01
(2)
2008-11
(4)
2008-09
(1)
2008-07
(1)
2008-06
(3)
2008-05
(4)
2008-03
(1)
2008-01
(5)
2007-08
(1)
2007-07
(9)
2007-06
(1)
2007-04
(1)
2007-03
(3)
2007-02
(3)
2007-01
(9)
2006-12 (36)
2006-11
(9)
2006-10
(32)
All Articles
(171)
Select :
--+ Home
--+ About Us
+ Areas of Research
--+ Basic Sciences Lab
+ Cardiology
+ Diabetes
+ Endocrinology
+ Gastrointestinal
+ Humanitarian Use Devices
+ Interventional Radiology
+ Nephrology and Hypertension
+ Neurology
+ Nutrition
+ Pediatrics
+ Pulmonary
+ Transplant
+ Wound Care Management
+ Vascular
+ Documents and Forms
+ In the Spotlight
+ Health Care Professionals
+ Patients and Families
+ Recent Publications
--+ 2010
+ 2009
+ 2008
+ 2007
+ 2006
+ 2005
+ 2004
+ 2003
+ 2002
+ 2001
+ Sponsors
Select :
--+ Home
--+ About Us
+ Areas of Research
--+ Basic Sciences Lab
+ Cardiology
+ Diabetes
+ Endocrinology
+ Gastrointestinal
+ Humanitarian Use Devices
+ Interventional Radiology
+ Nephrology and Hypertension
+ Neurology
+ Nutrition
+ Pediatrics
+ Pulmonary
+ Transplant
+ Wound Care Management
+ Vascular
+ Documents and Forms
+ In the Spotlight
+ Health Care Professionals
+ Patients and Families
+ Recent Publications
--+ 2010
+ 2009
+ 2008
+ 2007
+ 2006
+ 2005
+ 2004
+ 2003
+ 2002
+ 2001
+ Sponsors
Home
Home
Title
Date
2001
2001
GUSTO V: The bottom line of fibrinolytic reperfusion therapy.
2006-12-06 22:14:09
2001
2001
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial
2006-12-06 22:13:23
2001
2001
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
2006-12-06 22:12:39
2001
2001
Characteristics of 1514 Hypertensive patients at high coronary risk, The VALUE Trial.
2006-12-06 22:10:56
2001
2001
Grapefruit juice-drug interactions: Not just pulp fiction
2006-12-06 22:10:09
2001
2001
Doefetilide: A new Class III antiarrhythmic for the management of atrial fibrillation.
2006-12-06 22:09:17
2001
2001
Ischemic nephropathy.
2006-12-06 22:00:30
2001
2001
Sex differences in uric acid and risk factors for coronary artery disease.
2006-12-06 21:59:32
2001
2001
Ask the Experts: Please review the mechanisms of the anticoagulant and antithrombotic medications used in the treatment of acute coronary syndrome (ACA).
2006-12-06 21:58:35
2002
2002
Effects of amino acids and glucose on mesangial cell aminopeptidase A and angiotensin receptors
2006-12-06 21:57:43
2002
2002
Effect of amino acids and glucagon on renal hemodynamics in type 1 diabetes.
2006-12-06 21:56:46
2002
2002
Renal parenchymal injury as a determinant of clinical consequences in atherosclerotic renal artery stenosis
2006-12-06 21:55:17
2003
2003
Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: Heparin-induced thrombocytopenia in a high-risk cardiac surgical patient
2006-12-06 21:54:15
2003
2003
Provision of pharmacy services to underserved populations via remote dispensing and two-way video conferencing
2006-12-06 21:53:35
2003
2003
Predictors of acute renal failure after cardiac surgical procedures.
2006-12-06 21:52:37
2003
2003
Is there a pathogenic role for uric acid in hypertension, cardiovascular, and renal disease?
2006-12-06 21:51:43
2003
2003
Amino acids induce indicators of response to injury in glomerular mesangial cells.
2006-12-06 21:50:30
2003
2003
A novel potential therapy for diabetic nephropathy and vascular complications: Protein kinase C beta inhibition
2006-12-06 21:49:35
2004
2004
Cooking improved my quality of life as a CKD patient
2006-12-06 21:48:16
2004
2004
Atherosclerotic renal artery stenosis: Current status and future directions.
2006-12-06 21:47:31
2004
2004
Diabetic nephropathy: Implications for renal and cardiovascular outcomes.
2006-12-06 21:46:43
2004
2004
National Kidney Foundation - Kidney Disease Outcomes Quality Initiative (K/DOQI ) Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease.
2006-12-06 21:45:53
2004
2004
Cardiovascular implications of albuminuria.
2006-12-06 21:44:47
2004
2004
Primary hyperparathyroidism
2006-12-06 21:43:58
2005
2005
The next generation of diabetic nephropathy therapies: An update.
2006-12-06 20:20:52
2005
2005
A 60-year-old man with type 2 diabetes, hypertension, dyslipidemia, and albuminuria.
2006-12-06 20:14:46
2005
2005
The evaluation of diabetic nephropathy: Preventing complications.Johns Hopkins University School of Medicine.
2006-12-06 20:11:22
2005
2005
Uric Acid, microalbuminuria and cardiovascular events in high-risk patients.
2006-12-06 19:59:01
2005
2005
Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: A statistical modeling perspective.
2006-12-06 19:48:07
2005
2005
Renal manifestations of the metabolic syndrome.
2006-12-06 19:43:18
2005
2005
Cross specialty management of diabetic patients.
2006-12-06 19:27:31
2005
2005
Amino acid-induced protein kinase C activation and advanced glycation end-products formation in mesangial cells: Non-oxidant mechanisms.
2006-12-06 19:26:40
2006
2006
Major risks indicators for diabetic kidney disease
2006-12-06 19:20:13
2005
2005
Renal manifestations of the metabolic syndrome
2006-12-04 21:38:16
2005
2005
Cross specialty management of diabetic patients. Supplement to Diabetic Microvascular Complications Today 2005.
2006-12-04 21:14:10
-
-
Major risks indicators for diabetic kidney disease. In textbook Contemporary Diabetes: The Diabetic Kidney
2006-12-04 21:13:01
Options :
View Article Map
Notice of Privacy Practices
Providence Sacred Heart Medical Center
|
Joint Commission Notice
|
Joint Commission Web Site
© Copyright 2009 Providence Medical Research Center